LOS ANGELES, CA-- via eTeligis - SK3 Group (OTC Pink: SKTO) wishes to clarify certain statements made by Aventura Equities, Inc. ("Aventura") in its press release dated February 26, 2014 ("the Aventura Equities Release").
We have the utmost respect for our business partners at Aventura Equities. However, the Aventura Equities Release was made by the management of Aventura Equities without any prior notice, involvement, or approval of SKTO's management, which could have made the release more clear had it been obtained in advance.
Aventura has not acquired Berkeley Bio-Organic Research Laboratory ("Berkeley Bio"). Berkeley Bio remains a wholly-owned subsidiary of SKTO. In addition, although the transaction referenced resulted in Aventura receiving the rights to the intellectual property in the proprietary technology, processes, formulations, and marks of Berkeley Bio that have already been developed, SKTO remains, and will remain, the exclusive licensee of such intellectual property. The announced agreement/transfer does not permit Aventura to license others to use this intellectual property. In addition, the agreement announced by Aventura Equities does not cover future intellectual property developed by Berkeley Bio which will inure to the benefit of SKTO unless otherwise agreed. We have become aware of incorrect speculation that somehow this announcement impinges upon the rights of SKTO to its use of the Berkeley Bio technology, and that is simply incorrect.
"We continue to be a part of the SKTO family, and remain pleased that we are," said Berkeley Bio-Organic Research Laboratory Director David Hoye. "We remain a subsidiary company of SKTO and SKTO continues to be the sole and exclusive licensee of the proprietary technology, processes, and formulations developed by Berkeley Bio, and we look forward to remaining so for the long term. I would not be involved if it were otherwise."
About SKTO
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
Medical Greens
investors@medicalgreens.com
Investor Relations
SOURCE: SK3 Group, Inc.
Associated Documentation:
Link to submission on http://www.eteligis.com
SKTO_2-27-14_ETL_SMU.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment